Is checkpoint inhibitor pneumonitis underreported in patients with advanced non-small cell lung cancer (NSCLC) on PD-1 inhibitor monotherapy?

被引：2
|
作者：
Spieler, Benjamin Oren
Lopes, Gilberto
Dal Pra, Alan
Diwanji, Tejan
Yechieli, Raphael
Freedman, Laura M.
Mihaylov, Ivaylo
机构：
[1] Univ Miami, Miller Sch Med, Miami, FL 33136 USA
[2] Univ Miami Hlth Syst, Miami, FL USA
[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[4] Univ Miami, Parkland, FL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9579
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
    Luo, Jia
    Bandlamudi, Chaitanya
    Ricciuti, Biagio
    Vokes, Natalie
    Schoenfeld, Adam Jacob
    Egger, Jacklynn, V
    Sauter, Jennifer L.
    Plodkowski, Andrew J.
    Preeshagul, Isabel Ruth
    Kris, Mark G.
    Van Allen, Eliezer Mendel
    Taylor, Barry S.
    Rizvi, Hira
    Donoghue, Mark
    Awad, Mark M.
    Hellmann, Matthew David
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] 5-Year survival in Danish patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitor monotherapy
    Bjornhart, Birgitte
    Mouritzen, Mette Thune
    Kristiansen, Charlotte
    Schytte, Tine
    Wedervang, Kim
    Pohl, Mette
    Hansen, Karin Holmskov
    ACTA ONCOLOGICA, 2023, 62 (08) : 861 - 870
  • [33] SRC inhibitor saracatinib enhances efficacy of PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer
    Lu, Fei-Teng
    Luo, Fan
    Qiu, Miao-Zhen
    Cao, Jia-Xin
    Luo, Qiu-Yun
    Yang, Da-Jun
    Zhao, Hong-Yun
    CANCER RESEARCH, 2022, 82 (12)
  • [34] Impact of Rash Development for Patients with Non-Small Cell Lung Cancer Receiving PD-1/PD-L1-Based Immune Checkpoint Inhibitor Therapy
    Yang, Yongsheng
    EUROPEAN RESPIRATORY JOURNAL, 2024, 64
  • [35] Changes in skeletal muscle mass during PD-1 and PD-L1 checkpoint inhibitor therapy in advanced-stage non-small cell lung cancer patients.
    Multani, Maneet
    Tarhoni, Imad
    Fughhi, Ibdihaj
    Basu, Sanjib
    Batus, Marta
    Bonomi, Philip D.
    Fidler, Mary J.
    Borgia, Jeffrey Allen
    Shah, Palmi
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
    Min Luo
    Yuhui Xia
    Fang Wang
    Hong Zhang
    Danting Su
    Chaoyue Su
    Chuan Yang
    Shaocong Wu
    Sainan An
    Suxia Lin
    Liwu Fu
    Acta Pharmaceutica Sinica B, 2021, 11 (10) : 3120 - 3133
  • [37] PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma
    Luo, Min
    Xia, Yuhui
    Wang, Fang
    Zhang, Hong
    Su, Danting
    Su, Chaoyue
    Yang, Chuan
    Wu, Shaocong
    An, Sainan
    Lin, Suxia
    Fu, Liwu
    ACTA PHARMACEUTICA SINICA B, 2021, 11 (10) : 3120 - 3133
  • [38] Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer
    Chao, Yencheng
    Zhou, Jiebai
    Hsu, Shujung
    Ding, Ning
    Li, Jiamin
    Zhang, Yong
    Xu, Xiaobo
    Tang, Xinjun
    Wei, Tianchang
    Zhu, Zhengfei
    Chu, Qian
    Neal, Joel W.
    Wu, Julie Tsu-Yu
    Song, Yuanlin
    Hu, Jie
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (02) : 295 - +
  • [39] Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
    Li, Lijun
    Pu, Haihong
    Zhang, Xiaoxin
    Guo, Xiaotian
    Li, Guangrui
    Zhang, Minghui
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2025, 209
  • [40] Promising response to a PD-1 inhibitor (sintilimab) in non-small cell lung cancer A case report
    Zhang, Lin
    Mai, Wuqian
    Hao, Bo
    Jiang, Wenyang
    Geng, Qing
    MEDICINE, 2020, 99 (21) : E19790
12345